

Heikki Kuusanmäski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3306792/publications.pdf>

Version: 2024-02-01

29
papers

1,613
citations

949033

11
h-index

993246

17
g-index

30
all docs

30
docs citations

30
times ranked

3090
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401.	7.7	73
2	Endogenous and combination retinoids are active in myelomonocytic leukemias. <i>Haematologica</i> , 2021, 106, 1008-1021.	1.7	11
3	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. <i>Science Advances</i> , 2021, 7, .	4.7	28
4	Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells. <i>Blood Advances</i> , 2021, 5, 1862-1875.	2.5	5
5	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 71.	2.3	12
6	Identification of novel regulators of STAT3 activity. <i>PLoS ONE</i> , 2020, 15, e0230819.	1.1	12
7	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 708-720.	1.7	99
8	Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819.		0
9	Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819.		0
10	Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819.		0
11	Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819.		0
12	Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567.	5.8	107
13	Somatic <i>MED12</i> Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry. <i>Human Mutation</i> , 2017, 38, 269-274.	1.1	20
14	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. <i>Oncotarget</i> , 2017, 8, 22606-22615.	0.8	13
15	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. <i>Oncotarget</i> , 2017, 8, 56338-56350.	0.8	35
16	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. <i>Oncotarget</i> , 2017, 8, 97516-97527.	0.8	28
17	Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies. <i>Blood</i> , 2016, 128, 2921-2921.	0.6	0
18	In Silico and Ex Vivo Drug Screening Identifies Dasatinib as a Potential Targeted Therapy for T-ALL. <i>Blood</i> , 2016, 128, 4029-4029.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML. Blood, 2016, 128, 4711-4711.	0.6	0
20	Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood, 2015, 125, 639-648.	0.6	229
21	Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease. Blood, 2015, 126, 3006-3006.	0.6	0
22	Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells. Blood, 2015, 126, 700-700.	0.6	0
23	Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling. Blood, 2014, 124, 2160-2160.	0.6	0
24	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. Blood, 2014, 124, 2046-2046.	0.6	3
25	Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma. Blood, 2014, 124, 646-646.	0.6	0
26	Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies. Blood, 2014, 124, 1771-1771.	0.6	0
27	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood, 2013, 121, 4541-4550.	0.6	252
28	Novel Activating STAT5B Mutations As Drivers Of T-ALL. Blood, 2013, 122, 3863-3863.	0.6	5
29	Somatic <i>STAT3</i> Mutations in Large Granular Lymphocytic Leukemia. New England Journal of Medicine, 2012, 366, 1905-1913.	13.9	681